Bavarian Nordic partners up with Dynavax on hepatitis B vaccine

The two firms expect to launch the new vaccine in Germany in Q4 2021.

Photo: Bavarian Nordic / PR

Danish pharmaceutical company Bavarian Nordic is entering into a marketing and distribution agreement with Dynavac for the launch of a new hepatitis B vaccine in Germany, according to a press release published on Thursday.

Bavarian Nordic will market and distribute the Heplisav B vaccine for Dynavax. The companies expect it to be launched in the fourth quarter of 2021.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs